[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 53 of about 53
1. Futagbi G, Welbeck JE, Tetteh JK, Hviid L, Akanmori BD: Selective activation of TCR-gammadelta+ cells in endemic Burkitt's lymphoma. Malar J; 2007;6:69
Genetic Alliance. consumer health - Burkitt's Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective activation of TCR-gammadelta+ cells in endemic Burkitt's lymphoma.
  • BACKGROUND: The overlap in geographical distribution of Plasmodium falciparum malaria and endemic Burkitt's lymphoma (eBL)--an aggressive Epstein-Barr virus (EBV)-associated B-cell tumour occurring almost exclusively in the tropics--strongly suggests a link between the two diseases.
  • METHODS: Venous blood samples in heparin from 21 eBL patients (mean age: 7.0 years; range: 3-11 years), referred to the Burkitt's Tumour Centre at Korle-Bu Teaching Hospital, Accra and 15 healthy, age and sex matched children, were stained with fluorescein isothiocyanate (FITC)-, phycoerythrin (PE)-, R-phycoerythrin (RPE)- and RPE-Cy5-conjugated antibodies (CD3, CD4, CD8, CD25, CD69, CD95, HLA-DR, TCR-gammadelta, Vdelta1, Vdelta3, Vgamma9 and B-cells) and acquired on a flow cytometer.
  • [MeSH-major] Burkitt Lymphoma / immunology. Lymphocyte Activation. Malaria, Falciparum / complications. Malaria, Falciparum / immunology. Receptors, Antigen, T-Cell, gamma-delta / metabolism. T-Lymphocyte Subsets / immunology
  • [MeSH-minor] Child. Child, Preschool. Endemic Diseases. Female. Ghana / epidemiology. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FEMS Microbiol Immunol. 1991 Aug;3(4):219-27 [1931134.001]
  • [Cites] J Immunol. 1992 Dec 15;149(12):3984-9 [1334108.001]
  • [Cites] J Immunol Methods. 1993 Jan 4;157(1-2):135-42 [8423356.001]
  • [Cites] Am J Trop Med Hyg. 1994 Sep;51(3):372-9 [7524374.001]
  • [Cites] Eur J Immunol. 1994 Dec;24(12):3199-204 [7528674.001]
  • [Cites] J Immunol. 1997 Jan 1;158(1):464-74 [8977224.001]
  • [Cites] Infect Immun. 1996 Oct;64(10):4359-62 [8926112.001]
  • [Cites] Pediatr Hematol Oncol. 1999 Mar-Apr;16(2):149-58 [10100275.001]
  • [Cites] Am J Trop Med Hyg. 1991 May;44(5):571-7 [2063961.001]
  • [Cites] Int Immunol. 2000 Jun;12(6):797-805 [10837407.001]
  • [Cites] Infect Immun. 2001 May;69(5):3190-6 [11292740.001]
  • [Cites] J Natl Cancer Inst. 1969 Jan;42(1):19-28 [4303830.001]
  • [Cites] Am J Med. 1970 Mar;48(3):279-85 [4190958.001]
  • [Cites] Trans R Soc Trop Med Hyg. 1977;71(5):408-10 [304268.001]
  • [Cites] Clin Exp Immunol. 1978 Apr;32(1):41-5 [352584.001]
  • [Cites] Nature. 1978 Aug 24;274(5673):756-61 [210392.001]
  • [Cites] Int J Cancer. 1978 Dec;22(6):662-8 [214405.001]
  • [Cites] Nature. 1984 Nov 29-Dec 5;312(5993):398 [6095098.001]
  • [Cites] Nature. 1984 Nov 29-Dec 5;312(5993):449-50 [6095104.001]
  • [Cites] J Clin Oncol. 1987 Aug;5(8):1262-74 [3114436.001]
  • [Cites] Eur J Immunol. 1991 May;21(5):1249-53 [1674690.001]
  • (PMID = 17521425.001).
  • [ISSN] 1475-2875
  • [Journal-full-title] Malaria journal
  • [ISO-abbreviation] Malar. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Antigen, T-Cell, gamma-delta
  • [Other-IDs] NLM/ PMC1894981
  •  go-up   go-down


2. Tang W, Harmon P, Gulley ML, Mwansambo C, Kazembe PN, Martinson F, Wokocha C, Kenney SC, Hoffman I, Sigel C, Maygarden S, Hoffman M, Shores C: Viral response to chemotherapy in endemic burkitt lymphoma. Clin Cancer Res; 2010 Apr 1;16(7):2055-64
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Viral response to chemotherapy in endemic burkitt lymphoma.
  • We studied whether cyclophosphamide chemotherapy induces EBV to switch from latent to lytic phases of infection in a series of EBV-associated Burkitt lymphomas.
  • EXPERIMENTAL DESIGN: Children with first presentation of an expanding, solid maxillary or mandibular mass consistent with Burkitt lymphoma underwent fine-needle aspiration just prior to the initiation of cyclophosphamide therapy and again 1 to 5 days later.
  • RESULTS: Among 21 lymphomas expressing EBER prior to chemotherapy, 9 of 10 still expressed EBER on day 1 after therapy whereas only 2 of 11 (18%) specimens still expressed EBER at days 3 to 5, implying that chemotherapy was fairly effective at eliminating latently infected cells.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 AACR.
  • [Cites] J Virol. 2000 Nov;74(21):10223-8 [11024153.001]
  • [Cites] Haematologica. 2009 Nov;94(11):1618-22 [19608677.001]
  • [Cites] Antimicrob Agents Chemother. 2001 Jul;45(7):2082-91 [11408227.001]
  • [Cites] Transplantation. 2002 Jan 27;73(2):271-9 [11821743.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1920-6 [11912175.001]
  • [Cites] Med Pediatr Oncol. 2003 Jan;40(1):23-5 [12426682.001]
  • [Cites] Crit Rev Oncol Hematol. 2003 Jan;45(1):1-36 [12482570.001]
  • [Cites] Med Sci Monit. 2003 Jan;9(1):HY1-9 [12552250.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):965-71 [12615710.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):697-702, v-vi [12852651.001]
  • [Cites] J Virol. 2004 Feb;78(4):1893-902 [14747554.001]
  • [Cites] J Clin Oncol. 2004 Apr 15;22(8):1373-81 [15007085.001]
  • [Cites] Eur J Biochem. 2004 May;271(10):1895-905 [15128299.001]
  • [Cites] Diagn Mol Pathol. 2004 Jun;13(2):61-8 [15167006.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3053-60 [15284255.001]
  • [Cites] J Mol Diagn. 2004 Nov;6(4):378-85 [15507678.001]
  • [Cites] EMBO J. 1986 Oct;5(10):2599-607 [3023050.001]
  • [Cites] Cancer Res. 1989 Jan 1;49(1):1-7 [2491747.001]
  • [Cites] J Virol. 1989 Apr;63(4):1729-36 [2538653.001]
  • [Cites] J Virol. 1989 Jul;63(7):3109-16 [2542618.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Aug 1;88(15):6550-4 [1713681.001]
  • [Cites] Semin Cancer Biol. 1992 Oct;3(5):285-95 [1335792.001]
  • [Cites] Blood. 1995 Jul 15;86(2):659-65 [7605996.001]
  • [Cites] Cancer Res. 1996 Mar 1;56(5):969-72 [8640787.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Aug 20;93(17):9194-9 [8799177.001]
  • [Cites] Semin Cancer Biol. 1996 Aug;7(4):217-26 [8946606.001]
  • [Cites] Hum Gene Ther. 1998 May 20;9(8):1131-41 [9625252.001]
  • [Cites] J Virol. 1998 Oct;72(10):7978-84 [9733836.001]
  • [Cites] J Virol. 1998 Nov;72(11):9323-8 [9765483.001]
  • [Cites] Int J Cancer. 1999 Mar 31;81(1):6-11 [10077144.001]
  • [Cites] Cancer Res. 1999 Apr 1;59(7):1485-91 [10197618.001]
  • [Cites] Cancer. 1961 Mar-Apr;14:258-69 [14448554.001]
  • [Cites] J Natl Cancer Inst. 2004 Nov 17;96(22):1691-702 [15547182.001]
  • [Cites] Mod Pathol. 2005 Apr;18(4):519-27 [15696119.001]
  • [Cites] J Biol Chem. 2006 Nov 10;281(45):33871-80 [16956891.001]
  • [Cites] J Virol. 2007 Jan;81(2):1037-42 [17079287.001]
  • [Cites] Blood. 2007 Mar 15;109(6):2571-8 [17119113.001]
  • [Cites] Adv Cancer Res. 2007;97:81-109 [17419942.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2007;:277-84 [18024641.001]
  • [Cites] J Virol Methods. 2008 Jan;147(1):26-36 [17870188.001]
  • [Cites] FEBS Lett. 2008 Mar 5;582(5):705-9 [18258198.001]
  • [Cites] Trop Doct. 2008 Jan;38(1):7-11 [18302850.001]
  • [Cites] J Virol. 2008 May;82(10):4706-19 [18337569.001]
  • [Cites] J Mol Diagn. 2008 Jul;10(4):279-92 [18556771.001]
  • [Cites] Med Oncol. 2009;26(1):1-9 [18461290.001]
  • [Cites] Cancer Biol Ther. 2009 Jun;8(11):987-95 [19448399.001]
  • [Cites] J Virol. 2009 Oct;83(20):10694-709 [19656890.001]
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5781-8 [11059774.001]
  • (PMID = 20233888.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA066519; United States / NCI NIH HHS / CA / R01 CA058853; United States / NCI NIH HHS / CA / CA066519-16; United States / NCI NIH HHS / CA / R01-CA66519; United States / NCI NIH HHS / CA / R01 CA066519-16
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA, Viral; 8N3DW7272P / Cyclophosphamide
  • [Other-IDs] NLM/ NIHMS179000; NLM/ PMC2848899
  •  go-up   go-down


3. Ogwang MD, Bhatia K, Biggar RJ, Mbulaiteye SM: Incidence and geographic distribution of endemic Burkitt lymphoma in northern Uganda revisited. Int J Cancer; 2008 Dec 1;123(11):2658-63
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence and geographic distribution of endemic Burkitt lymphoma in northern Uganda revisited.
  • Endemic Burkitt lymphoma (BL) is etiologically associated with Epstein-Barr virus and ecologically linked to Plasmodium falciparum malaria.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • [Cites] Br J Cancer. 2000 May;82(9):1585-92 [10789729.001]
  • [Cites] Hum Genet. 1997 Nov;101(1):1-5 [9385359.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jun;50(6):1125-6 [18300307.001]
  • [Cites] Lancet Oncol. 2008 Apr;9(4):319 [18380064.001]
  • [Cites] Int J Cancer. 2008 Mar 15;122(6):1319-23 [18000823.001]
  • [Cites] Trop Med Int Health. 2007 Aug;12(8):936-43 [17697088.001]
  • [Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):962-72 [17565153.001]
  • [Cites] Int J Cancer. 2007 Jan 1;120(1):121-7 [17019706.001]
  • [Cites] Am J Trop Med Hyg. 2006 Aug;75(2):219-25 [16896122.001]
  • [Cites] Nat Genet. 1993 Sep;5(1):56-61 [8220424.001]
  • [Cites] IARC Sci Publ. 1985;(60):177-86 [3905588.001]
  • [Cites] IARC Sci Publ. 1985;(60):155-64 [4065944.001]
  • [Cites] IARC Sci Publ. 1984;(63):665-74 [6536627.001]
  • [Cites] J Clin Immunol. 1985 Mar;5(2):65-77 [3886684.001]
  • [Cites] Int J Cancer. 1980 Feb 15;25(2):197-203 [7390649.001]
  • [Cites] Int J Cancer. 1979 Mar 15;23(3):330-6 [437917.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2419-30 [16760442.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):985-90 [16106415.001]
  • [Cites] Community Dent Health. 2005 Sep;22(3):146-50 [16161877.001]
  • [Cites] West Afr J Med. 2005 Apr-Jun;24(2):139-42 [16092315.001]
  • [Cites] Early Hum Dev. 2005 Jan;81(1):123-9 [15707724.001]
  • [Cites] Nat Rev Microbiol. 2005 Feb;3(2):182-7 [15685227.001]
  • [Cites] Lancet Oncol. 2004 Dec;5(12):738-46 [15581545.001]
  • [Cites] Br J Surg. 1958 Nov;46(197):218-23 [13628987.001]
  • [Cites] J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):527-33 [12679705.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):673-96, v [12852650.001]
  • [Cites] Br J Cancer. 1969 Jun;23(2):235-46 [5788031.001]
  • [Cites] Br Med J. 1971 May 29;2(5760):491-2 [4325452.001]
  • [Cites] Lancet. 1974 Jul 6;2(7871):19-22 [4134408.001]
  • [Cites] Ann Intern Med. 1975 Jul;83(1):31-6 [1147436.001]
  • [Cites] Br J Cancer. 1977 May;35(5):668-73 [861150.001]
  • [Cites] Br J Cancer. 1978 Jan;37(1):109-22 [619954.001]
  • [Cites] Nature. 1978 Aug 24;274(5673):756-61 [210392.001]
  • [Cites] AIDS. 2000 Dec 22;14(18):2929-36 [11153674.001]
  • (PMID = 18767045.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / / Z01 CP010150-08; United States / NCI NIH HHS / CP / N02CP31003; United States / NCI NIH HHS / CP / N02-CP-31003; United States / NCI NIH HHS / CA / N01CO12400; United States / NCI NIH HHS / CO / N01-CO-12400
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS54919; NLM/ PMC2574984
  •  go-up   go-down


Advertisement
4. Koffi KG, N'dathz E, Tolo A, Nanho DC, Meite N, Ayemou R, Kouehion P, Sanogo I: [Rare localisations of endemic Burkitt lymphoma: about 21 cases observed in the Haematology Department of the University Hospital of Yopougon Abidjan]. Sante; 2010 Apr-Jun;20(2):69-72

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Rare localisations of endemic Burkitt lymphoma: about 21 cases observed in the Haematology Department of the University Hospital of Yopougon Abidjan].
  • [Transliterated title] Localisations exceptionnelles du Lymphome endémique de Burkitt (à propos de 21 cas vus en Côte d'Ivoire).
  • In this retrospective study, we analysed rare localisations of Burkitt lymphoma observed in the Haematology Department of the University Hospital of Yopougon Abidjan.
  • Over a 10-year study period, we saw 106 patients with Burkitt lymphoma, 21 with unusual localisations.
  • There were 8 cases of primary Burkitt lymphoma in a rare localisation and 13 cases of unusual localisations of secondary lymphomas.
  • In conclusion, the rare forms of Burkitt lymphoma are non-specific and can be mistaken for other solid tumours.
  • Diagnosis should thus be based on histochemical analysis.
  • [MeSH-major] Burkitt Lymphoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20685641.001).
  • [ISSN] 1157-5999
  • [Journal-full-title] Santé (Montrouge, France)
  • [ISO-abbreviation] Sante
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


5. Olowu WA, Adelusola KA, Badmos KB, Aina OJ: Autopsy diagnosis of endemic burkitt lymphoma as the primary etiology of acute renal failure in children. Pediatr Hematol Oncol; 2005 Jun;22(4):315-21

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autopsy diagnosis of endemic burkitt lymphoma as the primary etiology of acute renal failure in children.
  • Two cases of Burkitt lymphoma are reported who presented atypically with acute renal failure and significant proteinuria as initial features of the lymphoma.
  • The cases underscore the need for high index of suspicion for Burkitt lymphoma in any child with rapidly enlarging kidneys and acute renal failure of obscured origin in parts of the world where Burkitt lymphoma is endemic.
  • [MeSH-major] Acute Kidney Injury / etiology. Burkitt Lymphoma / diagnosis
  • [MeSH-minor] Adolescent. Autopsy. Child, Preschool. Diagnosis, Differential. Endemic Diseases. Fatal Outcome. Female. Humans. Kidney Medulla / pathology. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16020119.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


6. Moormann AM, Heller KN, Chelimo K, Embury P, Ploutz-Snyder R, Otieno JA, Oduor M, Münz C, Rochford R: Children with endemic Burkitt lymphoma are deficient in EBNA1-specific IFN-gamma T cell responses. Int J Cancer; 2009 Apr 1;124(7):1721-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Children with endemic Burkitt lymphoma are deficient in EBNA1-specific IFN-gamma T cell responses.
  • Endemic Burkitt lymphoma (eBL) is the most common childhood cancer in equatorial Africa and is linked to Epstein-Barr virus (EBV) and Plasmodium falciparum coinfections early in life.
  • In addition, CD4(+) T cell responses to a malaria protein, merozoite surface protein 1, were present in lymphoma patients.
  • This study demonstrates a selective loss of EBNA1-specific T cell responses in children with eBL and suggests a potential immunotherapeutic target for this EBV-associated lymphoma.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2001 Apr 29;356(1408):461-73 [11313005.001]
  • [Cites] J Immunol. 2008 Feb 1;180(3):1451-61 [18209040.001]
  • [Cites] Science. 2003 Sep 5;301(5638):1371-4 [12958359.001]
  • [Cites] J Virol. 2003 Nov;77(22):12088-104 [14581546.001]
  • [Cites] Infect Immun. 2003 Dec;71(12):6766-74 [14638762.001]
  • [Cites] J Exp Med. 2004 Feb 16;199(4):459-70 [14769850.001]
  • [Cites] Tissue Antigens. 2004 Apr;63(4):293-325 [15009803.001]
  • [Cites] IARC Sci Publ. 1985;(60):165-76 [2998987.001]
  • [Cites] Nature. 1995 Jun 22;375(6533):685-8 [7540727.001]
  • [Cites] Immunity. 1997 Dec;7(6):791-802 [9430224.001]
  • [Cites] Nature. 1999 Jul 1;400(6739):73-7 [10403251.001]
  • [Cites] East Afr Med J. 2004 Aug;(8 Suppl):S68-77 [15622605.001]
  • [Cites] J Infect Dis. 2005 Apr 15;191(8):1233-8 [15776368.001]
  • [Cites] Blood. 2005 Nov 1;106(9):3166-74 [16014568.001]
  • [Cites] Nat Immunol. 2006 Feb;7(2):165-72 [16415871.001]
  • [Cites] J Clin Microbiol. 2006 Apr;44(4):1459-67 [16597877.001]
  • [Cites] Int J Cancer. 2007 Jan 1;120(1):121-7 [17019706.001]
  • [Cites] Blood. 2007 Feb 1;109(3):1138-46 [16985171.001]
  • [Cites] J Infect Dis. 2007 Mar 15;195(6):799-808 [17299709.001]
  • [Cites] J Immunol. 2002 Aug 1;169(3):1593-603 [12133989.001]
  • (PMID = 19089927.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA108609; United States / NIAID NIH HHS / AI / AI4390; United States / FIC NIH HHS / TW / D43 TW006576; United States / NCI NIH HHS / CA / R01 CA101741; United States / NIAID NIH HHS / AI / U01 AI043906; United States / NIAID NIH HHS / AI / R01 AI043906; United States / NCI NIH HHS / CA / R01 CA134051; United States / NIAID NIH HHS / AI / K08 AI051565; United States / NCI NIH HHS / CA / CA101741; United States / FIC NIH HHS / TW / D43 TW006576-05; United States / NIAID NIH HHS / AI / K08-AI51565; United States / NIAID NIH HHS / AI / K08 AI051565-05; United States / NCI NIH HHS / CA / CA108609; United States / NCI NIH HHS / CA / R01 CA102667
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EBV-encoded nuclear antigen 1; 0 / Epstein-Barr Virus Nuclear Antigens; 0 / Immunoglobulin G; 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ NIHMS98574; NLM/ PMC2708320
  •  go-up   go-down


7. De Falco G, Leucci E, Lenze D, Piccaluga PP, Claudio PP, Onnis A, Cerino G, Nyagol J, Mwanda W, Bellan C, Hummel M, Pileri S, Tosi P, Stein H, Giordano A, Leoncini L: Gene-expression analysis identifies novel RBL2/p130 target genes in endemic Burkitt lymphoma cell lines and primary tumors. Blood; 2007 Aug 15;110(4):1301-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene-expression analysis identifies novel RBL2/p130 target genes in endemic Burkitt lymphoma cell lines and primary tumors.
  • Burkitt lymphoma (BL) is a B-cell tumor whose characteristic gene aberration is the translocation t(8;14), which determines c-myc overexpression.
  • We then monitored their expression in primary tumors of endemic BL as well, demonstrating that their expression resembled those of the BL cell lines.
  • [MeSH-major] Biomarkers, Tumor / genetics. Burkitt Lymphoma / genetics. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Mutation / genetics. Retinoblastoma-Like Protein p130 / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17485552.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA60999
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RBL2 protein, human; 0 / Retinoblastoma-Like Protein p130
  •  go-up   go-down


8. Tolo-Diebkilé A, Koffi GK, Nanho CD, Sawadogo D, Kouakou B, Siransi-Bogui L, Ayémou R, Sanogo I: [Evaluation of the protocol CMA reinforced in the treatment of endemic Burkitt lymphoma at CHU of Yopougon in Abidjan]. Bull Cancer; 2010 May;97(5):507-9
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of the protocol CMA reinforced in the treatment of endemic Burkitt lymphoma at CHU of Yopougon in Abidjan].
  • [Transliterated title] Evaluation du protocole CMA renforcé dans le traitement du lymphome de Burkitt endémique au CHU de Yopougon à Abidjan.
  • We report the results of the protocol CMA (cyclophosphamide, methotrexate, Aracytine) reinforced of 26 patients affected by Burkitt lymphoma in facial-maxillary localisation, in a retrospective study from January 2000 till December 2007 and prospective from January till September 2008.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Facial Neoplasms / drug therapy. Maxillary Neoplasms / drug therapy

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20071300.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


9. Rainey JJ, Rochford R, Sumba PO, Kowuor D, Wilson ML, Moormann AM: Family environment is associated with endemic Burkitt lymphoma: a population-based case-control study. Am J Trop Med Hyg; 2008 Feb;78(2):338-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Family environment is associated with endemic Burkitt lymphoma: a population-based case-control study.
  • Endemic Burkitt's lymphoma (eBL) has been linked to Epstein-Barr virus and holoendemic Plasmodium falciparum malaria.
  • These co-infections, however, are insufficient to explain the non-random occurrence of Endemic Burkitt's lymphoma within Equatorial Africa.
  • To explore whether this distribution could be explained by household characteristics and family environment, we conducted a case-control study using 41 hospitalized incident endemic Burkitt's lymphoma cases and 91 healthy controls identified through a population-based multistage cluster-sampling scheme in Nyanza Province, Kenya.
  • In a multivariate analysis, odds ratios associated with having one, two, and three or more younger siblings compared with none were 0.28 (90% CI: 0.09, 0.83), 0.59 (90% CI: 0.16, 2.23) and 0.15 (90% CI: 0.03, 0.67) respectively, suggesting that children with endemic Burkitt's lymphoma were more likely than controls to be last-born.
  • Children with endemic Burkitt's lymphoma were also more likely to live in non-monogamous families (OR=3.12, 90% CI:1.19, 8.17) and to have at least one deceased parent (OR=3.38, 90% CI: 1.18, 9.64).
  • Household characteristics, especially sibship relationships, may contribute to endemic Burkitt's lymphoma and therefore warrant further study.
  • [MeSH-major] Burkitt Lymphoma / epidemiology. Endemic Diseases. Family Characteristics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18256442.001).
  • [ISSN] 0002-9637
  • [Journal-full-title] The American journal of tropical medicine and hygiene
  • [ISO-abbreviation] Am. J. Trop. Med. Hyg.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / K08 AI051565
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


10. Gutiérrez-García L, Medina Ramos N, García Rodríguez R, Barber MA, Arias MD, García JA: Bilateral ovarian Burkitt's lymphoma. Eur J Gynaecol Oncol; 2009;30(2):231-3
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral ovarian Burkitt's lymphoma.
  • Primary ovarian lymphoma is a rare entity.
  • Histology confirmed Epstein-Barr virus-positive bilateral Burkitt's lymphoma.
  • Endemic Burkitt's lymphoma has a predilection for the female genital tract, manifesting itself clinically as a pelvic mass and less frequently as a menstrual disorder.
  • It is a rare entity in our environment but should be kept in mind when treating patients of African origin.
  • [MeSH-major] Burkitt Lymphoma / pathology. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19480266.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


11. Kurokawa M, Andela V, Ghosh S, Barreto JE, Harrington W: Zidovudine: a targeted therapy for endemic Burkitt's lymphoma. East Afr Med J; 2005 Sep;82(9 Suppl):S150-4
Hazardous Substances Data Bank. ZIDOVUDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Zidovudine: a targeted therapy for endemic Burkitt's lymphoma.
  • BACKGROUND: Although cyclophosphamide based regimens can produce remission rates approaching 60 to 80% in endemic Burkitts lymphoma, relapses and refractory disease are fairly common in developing countries, due to advanced stage disease and cost-constraints in the implementation of optimal chemotherapeutic protocols.
  • OBJECTIVE: To evaluate an affordable, tolerable and targeted approach to chemotherapy for endemic Burkitt's lymphoma as would be desirable in resource poor settings such as Africa.
  • DATA EXTRACTION: A systematic review to identify studies relating to Zidovudine, EBV+ and Burkitt's lymphoma, indicating antiviral agents zidovudine targeting BL in a unique and novel mechanisms.
  • CONCLUSION: Our data suggests that the incorporation of Zidovudine into Burkitt's regimens may enhance tumour kill and abbreviate the duration of treatment necessary for this disease.
  • Furthermore, the addition of the widely available and inexpensive agent hydroxyurea, markedly potentiates the tumorcidal activity of Zidovudine in Epstein Barr virus positive Burkitt's lymphomas.
  • [MeSH-major] Antiviral Agents / therapeutic use. Burkitt Lymphoma / drug therapy. Epstein-Barr Virus Infections / drug therapy. Zidovudine / therapeutic use

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16619691.001).
  • [ISSN] 0012-835X
  • [Journal-full-title] East African medical journal
  • [ISO-abbreviation] East Afr Med J
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] Kenya
  • [Chemical-registry-number] 0 / Antiviral Agents; 4B9XT59T7S / Zidovudine
  •  go-up   go-down


12. Bell AI, Groves K, Kelly GL, Croom-Carter D, Hui E, Chan AT, Rickinson AB: Analysis of Epstein-Barr virus latent gene expression in endemic Burkitt's lymphoma and nasopharyngeal carcinoma tumour cells by using quantitative real-time PCR assays. J Gen Virol; 2006 Oct;87(Pt 10):2885-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of Epstein-Barr virus latent gene expression in endemic Burkitt's lymphoma and nasopharyngeal carcinoma tumour cells by using quantitative real-time PCR assays.
  • When the new assays were used to screen a collection of endemic Burkitt's lymphoma tumours, abundant Qp-driven EBNA1 expression was found, whereas the other latent transcripts (with the exception of LMP2A) were either absent or detectable only at trace levels.
  • [MeSH-major] Burkitt Lymphoma / virology. Gene Expression Regulation, Viral. Herpesvirus 4, Human / genetics. Nasopharyngeal Neoplasms / virology. Virus Latency / genetics

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16963746.001).
  • [ISSN] 0022-1317
  • [Journal-full-title] The Journal of general virology
  • [ISO-abbreviation] J. Gen. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / RNA, Viral
  •  go-up   go-down


13. Chene A, Donati D, Orem J, Mbidde ER, Kironde F, Wahlgren M, Bejarano MT: Endemic Burkitt's lymphoma as a polymicrobial disease: new insights on the interaction between Plasmodium falciparum and Epstein-Barr virus. Semin Cancer Biol; 2009 Dec;19(6):411-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endemic Burkitt's lymphoma as a polymicrobial disease: new insights on the interaction between Plasmodium falciparum and Epstein-Barr virus.
  • Despite the well-established relationship between endemic Plasmodium falciparum malaria and Epstein-Barr virus (EBV) infection in the genesis of endemic Burkitt's lymphoma (eBL), very little research has examined the interaction between these two pathogens. eBL, the most prevalent childhood cancer in equatorial Africa where malaria is holoendemic, is a high-grade B cell lymphoma characterized by a c-myc translocation and the consistent presence of EBV.
  • African children are infected early in life and most have sero-converted by 3 years of age while sero-conversion tends to occur later in developed countries.
  • Following the observation of EBV reactivation in children living in malaria endemic areas and its relationship with acute malaria infection, we identified the cystein-rich inter-domain region 1 alpha (CIDR1 alpha) of the Plasmodium falciparum membrane protein 1 as a polyclonal B cell activator.
  • The increased viral load and the concomitant polyclonal B cell activation with enhanced B cell survival may augment the risk of eBL development in children living in malaria-endemic areas.
  • [MeSH-major] Burkitt Lymphoma / etiology. Epstein-Barr Virus Infections / complications. Herpesvirus 4, Human / pathogenicity. Malaria, Falciparum / complications. Plasmodium falciparum / pathogenicity

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19897039.001).
  • [ISSN] 1096-3650
  • [Journal-full-title] Seminars in cancer biology
  • [ISO-abbreviation] Semin. Cancer Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 100
  •  go-up   go-down


14. Harrison TM, McKnight CA, Sikarskie JG, Kitchell BE, Garner MM, Raymond JT, Fitzgerald SD, Valli VE, Agnew D, Kiupel M: Malignant lymphoma in african lions (panthera leo). Vet Pathol; 2010 Sep;47(5):952-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant lymphoma in african lions (panthera leo).
  • Malignant lymphoma has become an increasingly recognized problem in African lions (Panthera leo).
  • Eleven African lions (9 male and 2 female) with clinical signs and gross and microscopic lesions of malignant lymphoma were evaluated in this study.
  • Immunohistochemically, 10 of the 11 lions had T-cell lymphomas (CD3(+), CD79a(-)), and 1 lion was diagnosed with a B-cell lymphoma (CD3(-), CD79a(+)).
  • The spleen appeared to be the primary site of neoplastic growth in all T-cell lymphomas, with involvement of the liver (6/11) and regional lymph nodes (5/11) also commonly observed.
  • The B-cell lymphoma affected the peripheral lymph nodes, liver, and spleen.
  • According to the current veterinary and human World Health Organization classification of hematopoietic neoplasms, T-cell lymphoma subtypes included peripheral T-cell lymphoma (4/11), precursor (acute) T-cell lymphoblastic lymphoma/leukemia (2/11), chronic T-cell lymphocytic lymphoma/leukemia (3/11), and T-zone lymphoma (1/11).
  • The single B-cell lymphoma subtype was consistent with diffuse large B-cell lymphoma.
  • Feline leukemia virus (FeLV) and feline immunodeficiency virus (FIV) testing by immunohistochemistry on sections of malignant lymphoma was negative for all 11 lions.
  • In contrast to domestic and exotic cats, in which B-cell lymphomas are more common than T-cell lymphomas, African lions in this study had malignant lymphomas that were primarily of T-cell origin.
  • Neither FeLV nor FIV, important causes of malignant lymphoma in domestic cats, seems to be significant in the pathogenesis of malignant lymphoma in African lions.
  • [MeSH-major] Lions. Lymphoma / veterinary. Lymphoma, B-Cell / veterinary. Lymphoma, T-Cell / veterinary

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20610770.001).
  • [ISSN] 1544-2217
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Rainey JJ, Omenah D, Sumba PO, Moormann AM, Rochford R, Wilson ML: Spatial clustering of endemic Burkitt's lymphoma in high-risk regions of Kenya. Int J Cancer; 2007 Jan 1;120(1):121-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spatial clustering of endemic Burkitt's lymphoma in high-risk regions of Kenya.
  • Endemic Burkitt's lymphoma (eBL), the most common childhood cancer in sub-Saharan Africa, occurs at a high incidence in western Kenya, a region that also experiences holoendemic malaria.
  • [MeSH-major] Burkitt Lymphoma / epidemiology. Endemic Diseases

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17019706.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / K08 AI51565
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


16. Rochford R, Cannon MJ, Moormann AM: Endemic Burkitt's lymphoma: a polymicrobial disease? Nat Rev Microbiol; 2005 02;3(2):182-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endemic Burkitt's lymphoma: a polymicrobial disease?
  • Endemic Burkitt's lymphoma is the most common childhood cancer in equatorial Africa.
  • [MeSH-major] Burkitt Lymphoma / etiology. Endemic Diseases. Epstein-Barr Virus Infections / physiopathology. Herpesvirus 4, Human / pathogenicity. Malaria, Falciparum / physiopathology. Plasmodium falciparum / pathogenicity

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15685227.001).
  • [ISSN] 1740-1526
  • [Journal-full-title] Nature reviews. Microbiology
  • [ISO-abbreviation] Nat. Rev. Microbiol.
  • [Language] eng
  • [Publication-type] Review
  • [Publication-country] England
  •  go-up   go-down


17. Asito AS, Piriou E, Odada PS, Fiore N, Middeldorp JM, Long C, Dutta S, Lanar DE, Jura WG, Ouma C, Otieno JA, Moormann AM, Rochford R: Elevated anti-Zta IgG levels and EBV viral load are associated with site of tumor presentation in endemic Burkitt's lymphoma patients: a case control study. Infect Agent Cancer; 2010;5:13
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated anti-Zta IgG levels and EBV viral load are associated with site of tumor presentation in endemic Burkitt's lymphoma patients: a case control study.
  • BACKGROUND: Endemic Burkitt's lymphoma (BL) is an extranodal tumor appearing predominantly in the jaw in younger children while abdominal tumors predominate with increasing age.
  • Previous studies have identified elevated levels of antibodies to Plasmodium falciparum schizont extracts and Epstein-Barr virus (EBV) viral capsid antigens (VCA) in endemic BL relative to malaria exposed controls.
  • METHODS: We used a suspension bead Luminex assay to measure the IgG levels against EBV antigens, VCA, EAd, EBNA-1 and Zta as well as P. falciparum MSP-1, LSA-1, and AMA-1 antigens in children with BL (n = 32) and in population-based age-and sex-matched controls (n = 25) from a malaria endemic region in Western Kenya with high incidence of BL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Cancer Biol. 2009 Dec;19(6):377-88 [19619657.001]
  • [Cites] J Gen Virol. 1995 Jun;76 ( Pt 6):1393-400 [7540196.001]
  • [Cites] J Infect Dis. 1994 Jul;170(1):13-9 [8014488.001]
  • [Cites] Cancer. 1980 Mar 15;45(6):1507-15 [6244085.001]
  • [Cites] Nature. 1978 Aug 24;274(5673):756-61 [210392.001]
  • [Cites] Lancet. 1977 Feb 12;1(8007):335-8 [64861.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):757-68 [15510157.001]
  • [Cites] Arch Pathol Lab Med. 2004 May;128(5):549-52 [15086279.001]
  • [Cites] Cytometry. 2002 Oct 15;50(5):239-42 [12360572.001]
  • [Cites] Int J Cancer. 2002 Jun 10;99(5):635-43 [12115495.001]
  • [Cites] Int J Cancer. 2009 Apr 1;124(7):1721-6 [19089927.001]
  • [Cites] Nat Rev Microbiol. 2008 Dec;6(12):913-24 [19008891.001]
  • [Cites] Clin Vaccine Immunol. 2008 Nov;15(11):1684-8 [18768669.001]
  • [Cites] Int J Cancer. 2008 Dec 1;123(11):2658-63 [18767045.001]
  • [Cites] PLoS One. 2008;3(6):e2505 [18560562.001]
  • [Cites] Int J Cancer. 2008 Mar 15;122(6):1319-23 [18000823.001]
  • [Cites] J Clin Virol. 2008 Feb;41(2):96-103 [18024156.001]
  • [Cites] AIDS. 2007 Oct 18;21(16):2141-9 [18090040.001]
  • [Cites] Trop Med Int Health. 2007 Aug;12(8):936-43 [17697088.001]
  • [Cites] Int J Cancer. 2007 Jan 1;120(1):121-7 [17019706.001]
  • [Cites] Singapore Med J. 2006 Sep;47(9):803-7 [16924363.001]
  • [Cites] J Infect Dis. 2005 Apr 15;191(8):1233-8 [15776368.001]
  • [Cites] Anticancer Res. 2004 Nov-Dec;24(6):4059-66 [15736452.001]
  • [Cites] Nat Rev Microbiol. 2005 Feb;3(2):182-7 [15685227.001]
  • [Cites] East Afr Med J. 2004 Aug;(8 Suppl):S111-6 [15622609.001]
  • [Cites] Int J Cancer. 1999 Mar 31;81(1):6-11 [10077144.001]
  • [Cites] J Med Virol. 1999 Apr;57(4):383-9 [10089051.001]
  • [Cites] J Infect Dis. 1999 May;179(5):1108-15 [10191211.001]
  • [Cites] Ann Med. 1998 Jun;30(3):249-59 [9677010.001]
  • [Cites] Pediatr Pathol Lab Med. 1997 May-Jun;17(3):391-400 [9185219.001]
  • [Cites] Blood. 1996 Jun 15;87(12):5279-86 [8652843.001]
  • [Cites] Blood. 1995 Jul 15;86(2):659-65 [7605996.001]
  • [Cites] J Med Virol. 2009 Jun;81(6):1088-93 [19382256.001]
  • (PMID = 20667138.001).
  • [ISSN] 1750-9378
  • [Journal-full-title] Infectious agents and cancer
  • [ISO-abbreviation] Infect. Agents Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA102667
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2923120
  •  go-up   go-down


18. Moormann AM, Chelimo K, Sumba OP, Lutzke ML, Ploutz-Snyder R, Newton D, Kazura J, Rochford R: Exposure to holoendemic malaria results in elevated Epstein-Barr virus loads in children. J Infect Dis; 2005 Apr 15;191(8):1233-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Perennial and intense malaria transmission (holoendemic malaria) and Epstein-Barr virus (EBV) infection are 2 cofactors in the pathogenesis of endemic Burkitt lymphoma (eBL).

  • Genetic Alliance. consumer health - Malaria.
  • MedlinePlus Health Information. consumer health - Malaria.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15776368.001).
  • [ISSN] 0022-1899
  • [Journal-full-title] The Journal of infectious diseases
  • [ISO-abbreviation] J. Infect. Dis.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / K08 AI51565; United States / NIAID NIH HHS / AI / U01 AI43906
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


19. Park SS, Kim JS, Tessarollo L, Owens JD, Peng L, Han SS, Tae Chung S, Torrey TA, Cheung WC, Polakiewicz RD, McNeil N, Ried T, Mushinski JF, Morse HC 3rd, Janz S: Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice. Cancer Res; 2005 Feb 15;65(4):1306-15
SciCrunch. Marmoset Gene list: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The insertion of Myc(His) mimicked both the human t(8;14)(q24;q32) translocation that results in the activation of MYC in human endemic Burkitt lymphomas and the homologous mouse T(12;15) translocation that deregulates Myc in certain mouse plasmacytomas.
  • Beginning at the age of 6 months, Myc(His) transgenic mice developed B-cell and plasma neoplasms, such as IgM(+) lymphoblastic B-cell lymphomas, Bcl-6(+) diffuse large B-cell lymphomas, and CD138(+) plasmacytomas, with an overall incidence of 68% by 21 months.
  • Molecular studies of lymphoblastic B-cell lymphoma, the most prevalent neoplasm (50% of all tumors), showed that the lymphomas were clonal, overexpressed Myc(His), and exhibited the P2 to P1 promoter shift in Myc expression, a hallmark of MYC/Myc deregulation in human endemic Burkitt lymphoma and mouse plasmacytoma.
  • Only 1 (6.3%) of 16 lymphoblastic B-cell lymphomas contained a BL-typical point mutation in the amino-terminal transactivation domain of Myc(His), suggesting that most of these tumors are derived from naive, pregerminal center B cells.
  • Twelve (46%) of 26 lymphoblastic B-cell lymphomas exhibited changes in the p19(Arf)-Mdm2-p53 tumor suppressor axis, an important pathway for Myc-dependent apoptosis.
  • We conclude that Myc(His) insertion into Igh predictably induces B-cell and plasma-cell tumors in mice, providing a valuable mouse model for understanding the transformation-inducing consequences of the MYC/Myc-activating endemic Burkitt lymphoma t(8;14)/plasmacytoma T(12;15) translocation.
  • [MeSH-major] Chromosomes, Human, Pair 14 / genetics. Chromosomes, Human, Pair 8 / genetics. Genes, myc / genetics. Immunoglobulin Heavy Chains / genetics. Lymphoma, B-Cell / genetics. Plasmacytoma / genetics. Translocation, Genetic / genetics
  • [MeSH-minor] Amino Acid Sequence. Animals. B-Lymphocytes / physiology. Burkitt Lymphoma / genetics. Burkitt Lymphoma / pathology. Disease Models, Animal. Genes, Tumor Suppressor / physiology. Humans. Mice. Molecular Sequence Data. Point Mutation. Precancerous Conditions / genetics. Precancerous Conditions / pathology. Promoter Regions, Genetic. Transgenes


20. Moormann AM, Chelimo K, Sumba PO, Tisch DJ, Rochford R, Kazura JW: Exposure to holoendemic malaria results in suppression of Epstein-Barr virus-specific T cell immunosurveillance in Kenyan children. J Infect Dis; 2007 Mar 15;195(6):799-808
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Malaria and Epstein-Barr virus (EBV) infection are cofactors in the pathogenesis of endemic Burkitt lymphoma (eBL).
  • [MeSH-minor] Adolescent. Animals. Burkitt Lymphoma / epidemiology. Child. Child, Preschool. Humans. Kenya / epidemiology. Plasmodium falciparum

  • Genetic Alliance. consumer health - Malaria.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17299709.001).
  • [ISSN] 0022-1899
  • [Journal-full-title] The Journal of infectious diseases
  • [ISO-abbreviation] J. Infect. Dis.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / K08 AI51565; United States / NCI NIH HHS / CA / R01 CA102667; United States / NIAID NIH HHS / AI / U01 AI43906
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


21. Sow M, Nkégoum B, Oyono JL, Garoua, Nzokou A: [Epidemiological and histological features of urogenital tumours in Cameroon]. Prog Urol; 2006 Feb;16(1):36-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: A total of 2,371 urogenital tumours were identified, corresponding to 520 prostatic adenocarcinomas, 1,066 cases of benign prostatic hyperplasia, 41 testicular tumours (9 seminomatous tumours, 7 non-seminomatous tumours, 18 lymphomas, 4 benign papillomas and 2 rhabdomyosarcomas of the spermatic cord), 169 bladder tumours (25 transitional cell carcinomas, 70 squamous cell carcinomas, 67 adenocarcinomas, 2 lymphomas, 1 sarcoma and 1 benign papilloma), and 136 kidney tumours (20 Wilms tumours, 87 renal cell carcinomas, 6 transitional cell carcinomas, 16 lymphomas, 2 other malignant tumours and 5 adenomas).
  • The urogenital tract can also be the site of endemic Burkitt lymphoma in this country.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16526537.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


22. Chêne A, Donati D, Guerreiro-Cacais AO, Levitsky V, Chen Q, Falk KI, Orem J, Kironde F, Wahlgren M, Bejarano MT: A molecular link between malaria and Epstein-Barr virus reactivation. PLoS Pathog; 2007 Jun;3(6):e80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although malaria and Epstein-Barr (EBV) infection are recognized cofactors in the genesis of endemic Burkitt lymphoma (BL), their relative contribution is not understood.
  • BL, the most common paediatric cancer in equatorial Africa, is a high-grade B cell lymphoma characterized by c-myc translocation.
  • Our results suggest that P. falciparum antigens such as CIDR1alpha can directly induce EBV reactivation during malaria infection that may increase the risk of BL development for children living in malaria-endemic areas.

  • Genetic Alliance. consumer health - Malaria.
  • MedlinePlus Health Information. consumer health - Malaria.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virology. 1979 Apr 15;94(1):228-31 [220786.001]
  • [Cites] Nature. 1978 Mar 23;272(5651):373-5 [204874.001]
  • [Cites] Int J Cancer. 1984 Jan 15;33(1):27-32 [6319296.001]
  • [Cites] Trans R Soc Trop Med Hyg. 1983;77(6):879 [6665848.001]
  • [Cites] Science. 1986 Jun 20;232(4757):1554-6 [3012779.001]
  • [Cites] J Virol. 1989 Jan;63(1):445-9 [2462063.001]
  • [Cites] Trans R Soc Trop Med Hyg. 1988;82(5):657-9 [3075349.001]
  • [Cites] Adv Cancer Res. 1990;55:133-270 [2166998.001]
  • [Cites] Cell. 1994 Jan 28;76(2):263-74 [8293463.001]
  • [Cites] Int J Cancer. 1994 Jun 15;57(6):914-9 [8206684.001]
  • [Cites] Blood. 1997 Feb 1;89(3):919-28 [9028323.001]
  • [Cites] Infect Immun. 1998 Jun;66(6):2969-75 [9596774.001]
  • [Cites] J Virol. 2005 Jan;79(2):1296-307 [15613356.001]
  • [Cites] Malar J. 2004 Dec 15;3:50 [15601471.001]
  • [Cites] Nat Rev Microbiol. 2005 Feb;3(2):182-7 [15685227.001]
  • [Cites] J Infect Dis. 2005 Apr 15;191(8):1233-8 [15776368.001]
  • [Cites] Scand J Immunol. 2005 May;61(5):461-5 [15882438.001]
  • [Cites] J Infect Dis. 2006 Feb 1;193(3):422-6 [16388490.001]
  • [Cites] J Infect Dis. 2006 Apr 1;193(7):971-7 [16518759.001]
  • [Cites] J Med Microbiol. 2006 Jul;55(Pt 7):905-11 [16772418.001]
  • [Cites] J Immunol. 2006 Sep 1;177(5):3035-44 [16920940.001]
  • [Cites] J Virol. 2007 Feb;81(3):1390-400 [17108039.001]
  • [Cites] EMBO J. 2000 Jun 15;19(12):3080-9 [10856251.001]
  • [Cites] J Virol. 2000 Jul;74(14):6324-32 [10864642.001]
  • [Cites] J Exp Med. 2000 Jul 3;192(1):1-10 [10880521.001]
  • [Cites] J Virol. 2001 May;75(10):4482-9 [11312318.001]
  • [Cites] Science. 2001 Sep 14;293(5537):2098-100 [11557894.001]
  • [Cites] Immunity. 2002 May;16(5):745-54 [12049725.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):803-21 [14871955.001]
  • [Cites] FEMS Immunol Med Microbiol. 2004 May 1;41(1):9-26 [15094163.001]
  • [Cites] Infect Immun. 2004 Sep;72(9):5412-8 [15322039.001]
  • [Cites] J Natl Cancer Inst. 1969 Nov;43(5):1147-57 [5353242.001]
  • [Cites] Nat New Biol. 1973 Aug 15;244(137):214-7 [4353682.001]
  • [Cites] Clin Exp Immunol. 1983 Aug;53(2):335-44 [6349879.001]
  • (PMID = 17559303.001).
  • [ISSN] 1553-7374
  • [Journal-full-title] PLoS pathogens
  • [ISO-abbreviation] PLoS Pathog.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Protozoan; 0 / BZLF1 protein, Herpesvirus 4, Human; 0 / DNA, Viral; 0 / DNA-Binding Proteins; 0 / Protozoan Proteins; 0 / Trans-Activators; 0 / Viral Proteins; 0 / erythrocyte membrane protein 1, Plasmodium falciparum
  • [Other-IDs] NLM/ PMC1891325
  •  go-up   go-down


23. Tumwine LK, Orem J, Kerchan P, Byarugaba W, Pileri SA: EBV, HHV8 and HIV in B cell non Hodgkin lymphoma in Kampala, Uganda. Infect Agent Cancer; 2010;5:12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EBV, HHV8 and HIV in B cell non Hodgkin lymphoma in Kampala, Uganda.
  • BACKGROUND: B cell non Hodgkin lymphomas account for the majority of lymphomas in Uganda.
  • The commonest is endemic Burkitt lymphoma, followed by diffuse large-B-cell lymphoma (DLBCL).
  • There has been an increase in incidence of malignant lymphoma since the onset of the HIV/AIDS pandemic.
  • To describe the prevalence of Epstein-Barr virus, Human Herpes virus 8 and Human Immunodeficiency Virus-1 in B cell non Hodgkin lymphoma biopsy specimens in Kampala, Uganda.2.
  • To describe the histopathology of non Hodgkin lymphoma by HIV serology test result in Kampala, Uganda METHOD: Tumour biopsies specimens from 119 patients with B cell non Hodgkin lymphoma were classified according to the WHO classification.
  • Real time and nested PCR were used for the detection of HIV.The patients from whom the 1991-2000 NHL biopsies had been taken did not have HIV serology results therefore 145 patients biopsies where serology results were available were used to describe the association of HIV with non Hodgkin lymphoma type during 2008-2009.
  • RESULTS: In this study, the majority (92%) of the Burkitt lymphomas and only 34.8% of the diffuse large B cell lymphomas were EBV positive.
  • None of the precursor B lymphoblastic lymphomas or the mantle cell lymphomas showed EBV integration in the lymphoma cells.None of the Burkitt lymphoma biopsies had HIV by PCR.
  • Of the 121 non Hodgkin B cell lymphoma patients with HIV test results, 19% had HIV.
  • However, only 1(0.04%) case of Burkitt lymphoma had HIV.
  • CONCLUSIONS: The majority of the Burkitt lymphomas and two fifths of the diffuse large B cell lymphomas had EBV.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AIDS. 1991 Jun;5(6):669-74 [1652978.001]
  • [Cites] Blood. 2009 Feb 5;113(6):1213-24 [18955561.001]
  • [Cites] Rev Epidemiol Sante Publique. 1980 Oct 30;28(3):307-21 [6258200.001]
  • [Cites] Eur J Cancer Clin Oncol. 1983 Oct;19(10):1393-404 [6315443.001]
  • [Cites] Baillieres Clin Haematol. 1995 Mar;8(1):165-99 [7663046.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Apr 1;8(4):379-85 [7882103.001]
  • [Cites] Cancer Res. 1994 Apr 15;54(8):2069-72 [8174106.001]
  • [Cites] Int J Cancer. 1993 Apr 22;54(1):26-36 [8478145.001]
  • [Cites] J Exp Med. 1996 May 1;183(5):2385-90 [8642350.001]
  • [Cites] Hum Pathol. 1997 Mar;28(3):367-74 [9042803.001]
  • [Cites] Hum Pathol. 1997 Sep;28(9):1026-33 [9308726.001]
  • [Cites] Int J Cancer. 1998 Sep 11;77(6):817-20 [9714046.001]
  • [Cites] AIDS. 1998 Oct 1;12(14):1921-5 [9792393.001]
  • [Cites] Hum Pathol. 1998 Nov;29(11):1285-9 [9824108.001]
  • [Cites] N Engl J Med. 1999 Nov 11;341(20):1520-9 [10559454.001]
  • [Cites] Br J Cancer. 2000 May;82(9):1585-92 [10789729.001]
  • [Cites] J Natl Cancer Inst. 1977 May;58(5):1191-6 [192894.001]
  • [Cites] AIDS. 2000 Dec 22;14(18):2929-36 [11153674.001]
  • [Cites] J Virol. 2001 Feb;75(4):1857-63 [11160684.001]
  • [Cites] Int J Cancer. 2003 Sep 1;106(3):388-95 [12845679.001]
  • [Cites] Int J Cancer. 2004 Jan 1;108(1):66-70 [14618617.001]
  • [Cites] Curr HIV Res. 2004 Jul;2(3):215-21 [15279585.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):757-68 [15510157.001]
  • [Cites] PLoS Biol. 2005 Dec;3(12):e404 [16277553.001]
  • [Cites] J Infect Dis. 2006 Feb 1;193(3):422-6 [16388490.001]
  • [Cites] J Gen Virol. 2006 May;87(Pt 5):1047-74 [16603506.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 3;103(40):14935-40 [17001014.001]
  • [Cites] Oncogene. 2007 Aug 2;26(35):5115-23 [17325665.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1358-64 [17873116.001]
  • [Cites] Hum Pathol. 2008 Jun;39(6):817-23 [18436278.001]
  • [Cites] J Clin Virol. 2008 Nov;43(3):255-9 [18723390.001]
  • [Cites] Semin Cancer Biol. 2009 Dec;19(6):411-20 [19897039.001]
  • [Cites] AIDS. 2010 Feb 20;24(4):479-90 [20051807.001]
  • [Cites] Hum Pathol. 2007 Feb;38(2):308-14 [17097130.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3813-20 [18230756.001]
  • [Cites] BMC Infect Dis. 2008;8:111 [18706107.001]
  • [Cites] Adv Cancer Res. 1990;55:133-270 [2166998.001]
  • (PMID = 20591151.001).
  • [ISSN] 1750-9378
  • [Journal-full-title] Infectious agents and cancer
  • [ISO-abbreviation] Infect. Agents Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2907314
  •  go-up   go-down


24. Hesseling PB, Molyneux E, Kamiza S, Broadhead R: Rescue chemotherapy for patients with resistant or relapsed endemic Burkitt's lymphoma. Trans R Soc Trop Med Hyg; 2008 Jun;102(6):602-7
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rescue chemotherapy for patients with resistant or relapsed endemic Burkitt's lymphoma.
  • Patients with endemic Burkitt's lymphoma who failed primary treatment with the Malawi 2002 or 2003 Burkitt's lymphoma treatment protocols, consisting of high frequency cyclophosphamide 40 mg/kg and intrathecal methotrexate, were offered rescue chemotherapy.
  • This simple 15-day chemotherapy schedule salvaged 36% of patients and significantly increased the overall cure rate of our Burkitt's lymphoma patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Salvage Therapy / methods

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18417177.001).
  • [ISSN] 0035-9203
  • [Journal-full-title] Transactions of the Royal Society of Tropical Medicine and Hygiene
  • [ISO-abbreviation] Trans. R. Soc. Trop. Med. Hyg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


25. Yone CL, Kube D, Kremsner PG, Luty AJ: Persistent Epstein-Barr viral reactivation in young African children with a history of severe Plasmodium falciparum malaria. Trans R Soc Trop Med Hyg; 2006 Jul;100(7):669-76
Genetic Alliance. consumer health - Malaria.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Persistent Epstein-Barr viral reactivation in young African children with a history of severe Plasmodium falciparum malaria.
  • Epstein-Barr virus (EBV) and Plasmodium falciparum have overlapping distributions and are thought to have causal interactions, particularly with regard to the aetiology of endemic Burkitt's lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16313933.001).
  • [ISSN] 0035-9203
  • [Journal-full-title] Transactions of the Royal Society of Tropical Medicine and Hygiene
  • [ISO-abbreviation] Trans. R. Soc. Trop. Med. Hyg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimalarials; 0 / Cytokines; 0 / DNA, Viral
  •  go-up   go-down


26. Klumb CE, Magluta EP, Rezende LM, Apa AG, Alonso JF, Maia RC: Retinoblastoma-related geneRb2/p130 are rarely mutated in Burkitt's lymphoma from Brazil. Am J Hematol; 2007 Mar;82(3):238-9
Genetic Alliance. consumer health - Burkitt's Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retinoblastoma-related geneRb2/p130 are rarely mutated in Burkitt's lymphoma from Brazil.
  • It has been suggested that alterations of cell cycle genes probably contribute to the pathogenesis of endemic Burkitt's lymphoma (BL) in addition to c-MYC translocation.
  • Mutations disrupting the normal nuclear localization signal of the retinoblastoma-related gene Rb2/p130 have been documented in BL cell lines and primary tumors from endemic areas.
  • [MeSH-major] Burkitt Lymphoma / genetics. Point Mutation. Retinoblastoma-Like Protein p130 / genetics

  • Genetic Alliance. consumer health - Retinoblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16955460.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RBL2 protein, human; 0 / Retinoblastoma-Like Protein p130; 9007-49-2 / DNA
  •  go-up   go-down


27. Lubega J: T-helper 1 versus T-helper 2 lymphocyte immunodysregulation is the central factor in genesis of Burkitt lymphoma: hypothesis. Infect Agent Cancer; 2007;2:10
HIV InSite. treatment guidelines - Malaria and HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-helper 1 versus T-helper 2 lymphocyte immunodysregulation is the central factor in genesis of Burkitt lymphoma: hypothesis.
  • BACKGROUND: The HIV epidemic has challenged our previous understanding of endemic Burkitt's lymphoma.
  • Despite the strong association of Burkitt's lymphoma and HIV infection in the Developed world, and against previous postulations that the cancer is due to immunosupression among African children, the HIV epidemic in the Malaria belt has not been associated with a corresponding increase in incidence of childhood Burkitt's lymphoma.
  • Even outside the context of HIV infection, there is substantial evidence for a strong but skewed immune response towards a TH2 response in genesis of Burkitt lymphoma.
  • PRESENTATION OF THE HYPOTHESIS: Rather than a global and/or profound immunosupression, the final common pathway in genesis of Burkitt's lymphoma is the dysregulation of the immune response towards a TH2 response dominated by B-lymphocytes, and the concomitant suppression of the TH1 cell-mediated immune surveillance, driven by various viral/parasitic/bacterial infections.
  • TESTING THE HYPOTHESIS: Case control studies comparing TH2 and TH1 immune responses in Burkitt lymphoma of different etiological types (sporadic, HIV-related, endemic and post-transplant) to demonstrate significant dominance of TH2 immune response in presence of poor CMI response as a common factor.
  • Immunological profiling to evaluate differences between immune states that are associated (such as recurrent Malaria infection) and those that are not associated (such as severe protein-energy malnutrition) with Burkitt lymphoma.
  • Prospective cohorts profiling chronology of immunological events leading to Burkitt lymphoma in children with EBV infection.
  • IMPLICATIONS OF THE HYPOTHESIS: The dysregulation of the immune response may be the missing link in our understanding of Burkitt lymphomagenesis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] IARC Sci Publ. 1985;(60):177-86 [3905588.001]
  • [Cites] P N G Med J. 1986 Mar;29(1):41-3 [3019040.001]
  • [Cites] Proc R Soc Med. 1971 Sep;64(9):909-10 [4329792.001]
  • [Cites] Clin Exp Immunol. 1984 May;56(2):371-6 [6329564.001]
  • [Cites] Prog Food Nutr Sci. 1984;8(3-4):193-228 [6396715.001]
  • [Cites] Fed Proc. 1980 Nov;39(13):3098-104 [6968692.001]
  • [Cites] Int J Cancer. 1980 Sep 15;26(3):261-6 [7287207.001]
  • [Cites] Arch Dis Child. 1995 Aug;73(2):100-4; discussion 104-5 [7574850.001]
  • [Cites] Immunol Rev. 1994 Aug;140:73-92 [7821929.001]
  • [Cites] Int J Cancer. 1994 Oct 1;59(1):20-4 [7927898.001]
  • [Cites] AIDS. 1994 Aug;8(8):1025-49 [7986399.001]
  • [Cites] AIDS. 1996 Jun;10(6):643-7 [8780819.001]
  • [Cites] Am J Pathol. 1976 Sep;84(3):599-614 [8988.001]
  • [Cites] Ann Oncol. 1997 Oct;8(10):987-94 [9402172.001]
  • [Cites] Cancer. 1998 Feb 15;82(4):766-74 [9477111.001]
  • [Cites] Hum Pathol. 1998 Nov;29(11):1285-9 [9824108.001]
  • [Cites] Cent Afr J Med. 1998 Oct;44(10):242-5 [10101432.001]
  • [Cites] N Engl J Med. 2000 Aug 17;343(7):481-92 [10944566.001]
  • [Cites] AIDS. 2000 Dec 22;14(18):2929-36 [11153674.001]
  • [Cites] Int J Cancer. 2001 Jun 1;92(5):622-7 [11340563.001]
  • [Cites] Int J Cancer. 2001 Jun 1;92(5):687-91 [11340573.001]
  • [Cites] J Gen Virol. 2001 Dec;82(Pt 12):3051-5 [11714983.001]
  • [Cites] J Natl Cancer Inst. 1976 Mar;56(3):479-83 [1255780.001]
  • [Cites] Blood. 1992 Sep 1;80(5):1289-98 [1325212.001]
  • [Cites] Ann Med Interne (Paris). 2003 Dec;154(8):523-8 [15037828.001]
  • [Cites] Nat Rev Microbiol. 2005 Feb;3(2):182-7 [15685227.001]
  • [Cites] Int J Immunopharmacol. 1992 Apr;14(3):361-6 [1618590.001]
  • [Cites] Mol Immunol. 2007 Feb;44(5):934-42 [16730063.001]
  • [Cites] Pediatr Blood Cancer. 2007 May;48(5):515-20 [16794998.001]
  • [Cites] Transplantation. 2006 Oct 27;82(8):1013-23 [17060848.001]
  • [Cites] Eur J Cancer Prev. 2007 Feb;16(1):55-61 [17220705.001]
  • [Cites] Cancer. 1991 Dec 1;68(11):2466-72 [1933784.001]
  • [Cites] Int J Cancer. 1990 Apr 15;45(4):650-3 [2323841.001]
  • [Cites] Paediatr Perinat Epidemiol. 1990 Jul;4(3):303-24 [2374749.001]
  • [Cites] Am J Epidemiol. 1989 Apr;129(4):740-52 [2923122.001]
  • [Cites] Am J Med. 1970 Mar;48(3):279-85 [4190958.001]
  • (PMID = 17509139.001).
  • [ISSN] 1750-9378
  • [Journal-full-title] Infectious agents and cancer
  • [ISO-abbreviation] Infect. Agents Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1884132
  •  go-up   go-down


28. Rochford R, Feuer G, Orem J, Banura C, Katongole-Mbidde E, Mwanda WO, Moormann A, Harrington WJ, Remick SC: Strategies to overcome myelotoxic therapy for the treatment of Burkitt's and AIDS-related non-Hodgkin's lymphoma. East Afr Med J; 2005 Sep;82(9 Suppl):S155-60
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Strategies to overcome myelotoxic therapy for the treatment of Burkitt's and AIDS-related non-Hodgkin's lymphoma.
  • OBJECTIVES: To develop effective non-myelotoxic therapies for Burkitt's Lymphoma (BL) and AIDS-related non-Hodgkin's lymphoma.
  • CONCLUSION: Myelotoxic death rates using multi-agent induction chemotherapy approach 25% for endemic Burkitt's lymphoma and range between 20% to 60% for AIDS-related malignancy.
  • Investigations and alternative approaches that lessen or circumvent myelotoxicity of traditional cytotoxic chemotherapy for the management of Burkitt's lymphoma and AIDS-related non-Hodgkin's lymphoma in the resource-constrained setting are warranted.
  • This can be achieved by developing targeted anti-viral and other strategies, such as the use of bryostatin 1 and vincristine, and by developing a preclinical mouse model to frame the clinical rationale for a pilot trial of metronomic therapy for the treatment of Burkitt's and AIDS-related lymphoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Burkitt Lymphoma / drug therapy. Lymphoma, AIDS-Related / drug therapy. Macrolides / therapeutic use. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16619692.001).
  • [ISSN] 0012-835X
  • [Journal-full-title] East African medical journal
  • [ISO-abbreviation] East Afr Med J
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Kenya
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Bryostatins; 0 / Macrolides; 37O2X55Y9E / bryostatin 1; 5J49Q6B70F / Vincristine
  • [Number-of-references] 38
  •  go-up   go-down


29. Magrath I: Denis Burkitt and the African lymphoma. Ecancermedicalscience; 2009;3:159

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Denis Burkitt and the African lymphoma.
  • Burkitt lymphoma has provided a model for the understanding of the epidemiology, the molecular abnormalities that induce tumours, and the treatment of other lymphomas.
  • In addition, it is time to re-explore, with modern techniques, some of the questions that were raised some 50 years ago shortly after Burkitt's first description, as well as new questions that can be asked only in the light of modern understanding of the immune system and the molecular basis of tumor development.
  • The African lymphoma has taught us much, but there is a great deal still to be learned.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22276020.001).
  • [ISSN] 1754-6605
  • [Journal-full-title] Ecancermedicalscience
  • [ISO-abbreviation] Ecancermedicalscience
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3224008
  •  go-up   go-down


30. Magrath I: Lessons from clinical trials in African Burkitt lymphoma. Curr Opin Oncol; 2009 Sep;21(5):462-8
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lessons from clinical trials in African Burkitt lymphoma.
  • The present review focuses on the treatment of an AIDS-defining malignancy, Burkitt lymphoma, since the discovery of the tumor in 1958 to provide a backdrop to the increasing necessity of dealing with AIDS-associated Burkitt lymphoma in Africa.
  • RECENT FINDINGS: In Africa, it appears that AIDS-associated Burkitt lymphoma is increasing, but although treatment outcome is presently poor, the demonstration that highly active antiretroviral therapy permits the same treatment results to those in AIDS-unassociated Burkitt lymphoma provides hope for the future.
  • SUMMARY: In the 1960s, the extraordinary response of Burkitt lymphoma to chemotherapy provided considerable encouragement to pioneer oncologists.
  • The impact of the HIV epidemic on the epidemiology and treatment of African Burkitt lymphoma will receive increasing focus in the coming years.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Lymphoma, AIDS-Related / drug therapy

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19620863.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 64
  •  go-up   go-down


31. Amusa YB, Adediran IA, Akinpelu VO, Famurewa OC, Olateju SO, Adegbehingbe BO, Komolafe EO, Faponle AF, Olasode BJ: Burkitt's lymphoma of the head and neck region in a Nigerian tertiary hospital. West Afr J Med; 2005 Apr-Jun;24(2):139-42
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt's lymphoma of the head and neck region in a Nigerian tertiary hospital.
  • BACKGROUND: Burkitt's lymphoma is endemic in Nigeria; it forms about 39% of all childhood cancers.
  • OBJECTIVE: This study is designed to look at the pattern of presentation of head and Neck Burkitt's lymphoma at a Nigerian Tertiary hospital and to evaluate current treatment modality.
  • DESIGN: It is a retrospective study of all confirmed Burkitt's lymphoma of the head and neck region seen at the Obafemi Awolowo University Teaching Hospital Ile Ife (OAUTHC) between 1986 and 2002.
  • PATIENTS AND METHODS: The medical records of all the patients with the histopathologically confirmed Burkitt's lymphoma over a 17-year period (1986-2002) were evaluated.
  • RESULTS: A total of 196 cases of Burkitt's lymphoma were seen over the period out of which 140 (71.4%) were in the head and neck region.
  • CONCLUSION: Head and neck remain the mostly affected parts in Burkitt's lymphoma in this environment.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Head and Neck Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] West Afr J Med. 2005 Jul-Sep;24(3):189. Adegbeingbe, OD [corrected to Adegbehingbe, BO]
  • (PMID = 16092315.001).
  • [ISSN] 0189-160X
  • [Journal-full-title] West African journal of medicine
  • [ISO-abbreviation] West Afr J Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


32. Bolarinwa RA, Ndakotsu MA, Oyekunle AA, Salawu L, Akinola NO, Durosinmi MA: AIDS-related lymphomas in Nigeria. Braz J Infect Dis; 2009 Oct;13(5):359-61
Genetic Alliance. consumer health - AIDS-HIV.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related lymphomas in Nigeria.
  • Aggressive non-Hodgkin's lymphoma (NHL), including primary central nervous system (CNS) lymphoma, lymphoblastic lymphoma and non-endemic Burkitt's lymphoma have been recognized as AIDS-defining cancers in most developed countries.
  • However, HIV/AIDS epidemics appear not to have been associated with higher incidence of lymphomas in Africa.
  • We therefore carried out this study to highlight the significance or otherwise of HIV/AIDS epidemics in the pathogenesis of lymphomas in a population of Nigerians with the disease.
  • Patients with a histological diagnosis of malignant chronic lymphoproliferative diseases {non-Hodgkin lymphoma (NHL), chronic lymphocytic leukaemia (CLL), Burkitt's lymphoma (BL) and Hodgkin lymphoma (HL)} at the Obafemi Awolowo University Teaching Hospitals' Complex, Ile-Ife from January 1993 to August 2008 were noted.
  • Those patients confirmed to be HIV/AIDS positive among the cohort with lymphomas were retrospectively studied using their clinical case notes.
  • A total of 391 patients were histologically confirmed to have lymphoma {NHL-109, (27.9%); CLL-76, (19.4%); BL-178, (45.5%) and HL-28, (7.2%)} during the study period.
  • The prevalence of AIDS-related lymphomas is 2.3% compared to 4.4% found in the general population.
  • However, it is interesting that no single case of AIDS-associated BL was seen, despite the fact that Burkitt's lymphoma is endemic in this part of the world.
  • [MeSH-major] Lymphoma, AIDS-Related / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20428636.001).
  • [ISSN] 1678-4391
  • [Journal-full-title] The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
  • [ISO-abbreviation] Braz J Infect Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


33. Hesseling P, Molyneux E, Kamiza S, Israels T, Broadhead R: Endemic Burkitt lymphoma: a 28-day treatment schedule with cyclophosphamide and intrathecal methotrexate. Ann Trop Paediatr; 2009 Mar;29(1):29-34
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endemic Burkitt lymphoma: a 28-day treatment schedule with cyclophosphamide and intrathecal methotrexate.
  • BACKGROUND: Endemic Burkitt lymphoma (eBL) is the most common childhood cancer in equatorial Africa and there is a need for affordable, effective treatment.
  • The initial diagnosis was made clinically and confirmed by fine-needle aspiration in 73%.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19222931.001).
  • [ISSN] 1465-3281
  • [Journal-full-title] Annals of tropical paediatrics
  • [ISO-abbreviation] Ann Trop Paediatr
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


34. Calvert JG, Slade DE, Shields SL, Jolie R, Mannan RM, Ankenbauer RG, Welch SK: CD163 expression confers susceptibility to porcine reproductive and respiratory syndrome viruses. J Virol; 2007 Jul;81(14):7371-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Transient-transfection experiments showed that full-length CD163 cDNAs from PAM, human U937 cells (histiocytic lymphoma), African green monkey kidney cells (MARC-145 and Vero), primary mouse peritoneal macrophages, and canine DH82 (histocytosis) cells encode functional virus receptors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2002 Jan 1;99(1):378-80 [11756196.001]
  • [Cites] J Leukoc Biol. 2006 Apr;79(4):837-45 [16434690.001]
  • [Cites] J Virol Methods. 2002 Jul;104(2):203-16 [12088830.001]
  • [Cites] Vet Q. 2002 Jun;24(2):95-100 [12095084.001]
  • [Cites] FEBS Lett. 2002 Aug 28;526(1-3):93-6 [12208511.001]
  • [Cites] Viral Immunol. 2002;15(4):533-47 [12513925.001]
  • [Cites] Arch Virol. 2003 Jan;148(1):177-87 [12536303.001]
  • [Cites] J Virol. 2003 Aug;77(15):8207-15 [12857889.001]
  • [Cites] Emerg Infect Dis. 2003 Aug;9(8):903-8 [12967485.001]
  • [Cites] Arch Virol. 2003 Dec;148(12):2307-23 [14648288.001]
  • [Cites] Crit Rev Immunol. 2004;24(1):1-37 [14995912.001]
  • [Cites] Vet Immunol Immunopathol. 2004 Dec 8;102(3):143-54 [15507301.001]
  • [Cites] Eur J Immunol. 1993 Sep;23(9):2320-5 [8370408.001]
  • [Cites] Arch Virol. 1993;133(3-4):477-83 [8257302.001]
  • [Cites] J Clin Microbiol. 1993 Dec;31(12):3184-9 [7508455.001]
  • [Cites] Nucleic Acids Res. 1994 Nov 11;22(22):4673-80 [7984417.001]
  • [Cites] Virus Res. 1996 Jun;42(1-2):137-47 [8806181.001]
  • [Cites] Vet Microbiol. 1997 May;56(1-2):9-19 [9228678.001]
  • [Cites] Arch Virol. 1997;142(3):629-33 [9349308.001]
  • [Cites] J Virol. 1998 Jan;72(1):380-7 [9420236.001]
  • [Cites] J Virol. 1998 May;72(5):4520-3 [9557752.001]
  • [Cites] Arch Virol. 1997;142(12):2483-97 [9672608.001]
  • [Cites] Vet Res. 2000 Jan-Feb;31(1):61-9 [10726638.001]
  • [Cites] J Immunol. 2000 Dec 1;165(11):6406-15 [11086079.001]
  • [Cites] Nature. 2001 Jan 11;409(6817):198-201 [11196644.001]
  • [Cites] Virus Genes. 2001 Mar;22(2):209-17 [11324758.001]
  • [Cites] Immunogenetics. 2001 Mar;53(2):170-7 [11345593.001]
  • [Cites] J Gen Virol. 1999 Feb;80 ( Pt 2):297-305 [10073688.001]
  • [Cites] Mol Biol Evol. 2005 Apr;22(4):1024-31 [15659555.001]
  • [Cites] J Gen Virol. 2005 May;86(Pt 5):1441-5 [15831956.001]
  • [Cites] J Am Vet Med Assoc. 2005 Aug 1;227(3):385-92 [16121604.001]
  • [Cites] Immunobiology. 2005;210(2-4):153-60 [16164022.001]
  • [Cites] Mol Biol Evol. 2005 Nov;22(11):2131-4 [16000650.001]
  • [Cites] J Virol. 2006 Jan;80(2):689-96 [16378972.001]
  • [Cites] J Virol. 2002 May;76(9):4312-20 [11932397.001]
  • (PMID = 17494075.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD163 antigen; 0 / DNA Primers; 0 / Membrane Glycoproteins; 0 / RNA, Messenger; 0 / Receptors, Cell Surface; 0 / Receptors, Immunologic; 0 / SIGLEC1 protein, human; 0 / Sialic Acid Binding Ig-like Lectin 1; 0 / Siglec1 protein, mouse
  • [Other-IDs] NLM/ PMC1933360
  •  go-up   go-down


35. Phillips JA, Griffin BE: Pilot study of sodium phenylbutyrate as adjuvant in cyclophosphamide-resistant endemic Burkitt's lymphoma. Trans R Soc Trop Med Hyg; 2007 Dec;101(12):1265-9
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilot study of sodium phenylbutyrate as adjuvant in cyclophosphamide-resistant endemic Burkitt's lymphoma.
  • Burkitt's lymphoma (BL) accounts for the majority of childhood malignancies seen in sub-Saharan Africa.
  • In Malawi, cyclophosphamide (CPM), the mainstay of treatment for endemic BL, is effective in around 50% of cases.
  • It has also shown some success as adjuvant in treatment of chronic leukaemia and lymphoma.
  • We tested in African BL patients with CPM-resistant tumours, and thus unlikely to survive, the hypothesis that PB can reverse this resistance.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Antineoplastic Agents, Alkylating / therapeutic use. Burkitt Lymphoma / drug therapy. Cyclophosphamide / therapeutic use. Phenylbutyrates / therapeutic use

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17915270.001).
  • [ISSN] 0035-9203
  • [Journal-full-title] Transactions of the Royal Society of Tropical Medicine and Hygiene
  • [ISO-abbreviation] Trans. R. Soc. Trop. Med. Hyg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antineoplastic Agents, Alkylating; 0 / Phenylbutyrates; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


36. Kanai K, Satoh Y, Saiki Y, Ohtani H, Sairenji T: Difference of Epstein-Barr virus isolates from Japanese patients and African Burkitt's lymphoma cell lines based on the sequence of latent membrane protein 1. Virus Genes; 2007 Jan;34(1):55-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Difference of Epstein-Barr virus isolates from Japanese patients and African Burkitt's lymphoma cell lines based on the sequence of latent membrane protein 1.
  • To characterize the genomic relationship between Japanese EBV and the EBV isolates of other countries, we analyzed the LMP1 nucleotide sequences in EBV positive cell lines and clinical specimens, including five African Burkitt's lymphoma (BL) cell lines, a Japanese BL cell line, a B-lymphoblastoid cell line, a nasopharyngeal carcinoma hybrid cell line, six gastric carcinoma tissues, two peripheral blood mononuclear cells, and a B95-8 cell line, which contained the prototype EBV genome.
  • The results indicate that the Japanese EBV isolates are greatly different from the African BL isolates but are closely related to the China 1, which is a strain of Chinese EBV isolates.
  • [MeSH-major] Burkitt Lymphoma / virology. Herpesvirus 4, Human / genetics. Viral Matrix Proteins / genetics

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16917741.001).
  • [ISSN] 0920-8569
  • [Journal-full-title] Virus genes
  • [ISO-abbreviation] Virus Genes
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Viral Matrix Proteins
  •  go-up   go-down


37. Omoti AE, Omoti CE, Momoh RO: Ophthalmic disorders in adult lymphoma patients in Africa. Middle East Afr J Ophthalmol; 2009 Oct;16(4):252-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ophthalmic disorders in adult lymphoma patients in Africa.
  • CONTEXT: Ocular manifestations of lymphoma are rare events.
  • Most reports of ocular involvement in lymphoma are case reports or reports of a few patients.
  • AIMS: To determine the ophthalmic disorders in adult, African, lymphoma patients.
  • SETTINGS AND DESIGN: A prospective study of ocular disorders in adult patients with lymphoma was conducted at the University of Benin Teaching Hospital, Benin City, Nigeria, between July 2004 and June 2007.
  • RESULTS: A total of 111 patients with hematological malignancies were seen over a period of three years of which 62 (55.85%) had lymphomas.
  • Of these, 51(82.3%) were non-Hodgkin's lymphoma and 11(17.7%) were Hodgkin's lymphoma.
  • Ocular disorders occurred in 16 patients (31.4%) with non-Hodgkin's lymphoma and none of the patients with Hodgkin's lymphoma (Mann-Whitney U-statistic is equal to 7.500, U' is equal to161.50, P< 0.0001).
  • The ocular disorders due to non-Hodgkin's lymphoma were seen as - proptosis in six patients (11.8%), retinopathies in three (5.9%), conjunctival infiltration in three (5.9%), optic atrophy in two (3.9%), keratoconjunctivitis in one (two per cent), desquamating nodular lid lesions in one (two per cent), papilloedema in one (two per cent), and upper lid mass in one (two per cent).
  • CONCLUSIONS: Ophthalmic disorders are relatively common in non-Hodgkin's lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Hematol. 1997 Apr;74(4):163-8 [9174543.001]
  • [Cites] Ophthalmology. 1999 Jul;106(7):1339-44 [10406618.001]
  • [Cites] Ann Oncol. 2000;11 Suppl 1:3-10 [10707771.001]
  • [Cites] Surv Ophthalmol. 2001 May-Jun;45(6):463-71 [11425352.001]
  • [Cites] Ophthalmology. 2002 Sep;109(9):1717-22 [12208722.001]
  • [Cites] Curr Opin Ophthalmol. 2002 Dec;13(6):411-8 [12441846.001]
  • [Cites] Ann Afr Med. 2007 Sep;6(3):89-93 [18240494.001]
  • [Cites] Klin Monbl Augenheilkd. 2004 May;221(5):401-3 [15162291.001]
  • [Cites] Med J Malaysia. 2003 Oct;58(4):546-55 [15190631.001]
  • [Cites] Klin Oczna. 2004;106(6):783-7 [15787182.001]
  • [Cites] Clin Lab Haematol. 2005 Oct;27(5):302-6 [16178909.001]
  • [Cites] Can J Ophthalmol. 2005 Oct;40(5):623-6 [16391629.001]
  • [Cites] Ophthalmology. 2003 May;110(5):1057-60 [12750114.001]
  • (PMID = 20404992.001).
  • [ISSN] 0975-1599
  • [Journal-full-title] Middle East African journal of ophthalmology
  • [ISO-abbreviation] Middle East Afr J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2855666
  • [Keywords] NOTNLM ; Lymphoma / Ophthalmic Disorders / Proptosis
  •  go-up   go-down


38. Owusu L, Yeboah FA, Osei-Akoto A, Rettig T, Arthur FK: Clinical and epidemiological characterisation of Burkitt's lymphoma: an eight-year case study at Komfo Anokye Teaching Hospital, Ghana. Br J Biomed Sci; 2010;67(1):9-14
Genetic Alliance. consumer health - Burkitt's Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and epidemiological characterisation of Burkitt's lymphoma: an eight-year case study at Komfo Anokye Teaching Hospital, Ghana.
  • Endemic Burkitt's lymphoma (BL) is a juvenile malignant neoplasm of B-lymphocyte origin, markedly affected by climate, vegetation and geographical location.
  • This real country-based, cross-sectional, retrospective study reviews all out-patient clinical records of patients histologically and/or clinically diagnosed with BL from January, 2000 to December, 2007 at the Komfo Anokye Teaching Hospital, Ghana, a country within the malaria and lymphoma belts of the world.
  • [MeSH-major] Burkitt Lymphoma / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Br J Biomed Sci. 2010;67(2):101
  • (PMID = 20373676.001).
  • [ISSN] 0967-4845
  • [Journal-full-title] British journal of biomedical science
  • [ISO-abbreviation] Br. J. Biomed. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


39. Kanai K, Satoh Y, Yamanaka H, Kawaguchi A, Horie K, Sugata K, Hoshikawa Y, Sata T, Sairenji T: The vIL-10 gene of the Epstein-Barr virus (EBV) is conserved in a stable manner except for a few point mutations in various EBV isolates. Virus Genes; 2007 Dec;35(3):563-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In order to further elucidate the variations of EBV strains, the BCRF1 (vIL-10) gene was analyzed using PCR-direct sequencing in African Burkitt's lymphoma (BL) cell lines Raji, P3HR-1, EB1 and Daudi, Japanese BL cell line Akata, lymphoblastoid cell line OB and 22 wild EBV isolates from eight gastric carcinoma tissues and 14 throat washes.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17763933.001).
  • [ISSN] 0920-8569
  • [Journal-full-title] Virus genes
  • [ISO-abbreviation] Virus Genes
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / IL-10 like protein, Human herpesvirus 5; 0 / Viral Proteins
  •  go-up   go-down


40. Kelly GL, Milner AE, Baldwin GS, Bell AI, Rickinson AB: Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells. Proc Natl Acad Sci U S A; 2006 Oct 3;103(40):14935-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells.
  • For example, endemic Burkitt lymphoma (BL) classically presents as a monoclonal, c-myc-translocation-positive tumor in which every cell carries EBV as an EBNA1-only (Latency I) infection; such homogeneity among EBV-positive cells, and the lack of EBV-negative comparators, hampers attempts to understand EBV's role in BL pathogenesis.
  • Here, we describe an endemic BL that was unusually heterogeneous at the single-cell level and, in early passage culture, yielded a range of cellular clones, all with the same c-myc translocation but differing in EBV status.
  • [MeSH-major] Apoptosis. Burkitt Lymphoma / metabolism. Herpesvirus 4, Human / physiology. Proto-Oncogene Proteins c-myc / metabolism. Virus Latency / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 2002 Oct;8(10):1098-104 [12219084.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11878-83 [12195020.001]
  • [Cites] Virology. 2003 Feb 15;306(2):236-43 [12642097.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4730-5 [12665622.001]
  • [Cites] Nat Rev Immunol. 2003 Oct;3(10):801-12 [14523386.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14269-74 [14603034.001]
  • [Cites] J Virol. 2004 Nov;78(22):12694-7 [15507659.001]
  • [Cites] Gene. 1984 Mar;27(3):279-88 [6329907.001]
  • [Cites] EMBO J. 1987 Sep;6(9):2743-51 [2824192.001]
  • [Cites] J Virol. 1990 May;64(5):2126-34 [2157875.001]
  • [Cites] J Virol. 1990 Jul;64(7):3407-16 [2352328.001]
  • [Cites] Adv Cancer Res. 1990;55:133-270 [2166998.001]
  • [Cites] J Virol. 1991 Jan;65(1):415-23 [1845900.001]
  • [Cites] Nature. 1991 Feb 14;349(6310):612-4 [1705663.001]
  • [Cites] EMBO J. 1993 Aug;12(8):3277-86 [8393785.001]
  • [Cites] J Virol. 1994 Sep;68(9):6069-73 [8057484.001]
  • [Cites] Blood. 1995 Jul 15;86(2):659-65 [7605996.001]
  • [Cites] EMBO J. 1996 Jan 15;15(2):375-82 [8617212.001]
  • [Cites] J Virol. 1996 Jun;70(6):4179-83 [8648764.001]
  • [Cites] J Virol. 1996 Sep;70(9):5909-15 [8709211.001]
  • [Cites] J Virol. 1996 Aug;70(8):4895-903 [8763992.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 17;93(19):10411-6 [8816814.001]
  • [Cites] J Virol. 1998 Nov;72(11):9150-6 [9765461.001]
  • [Cites] Mol Cell Biol. 1999 Mar;19(3):1651-60 [10022853.001]
  • [Cites] Int J Cancer. 1999 Aug 20;84(4):442-8 [10404101.001]
  • [Cites] J Gen Virol. 2005 Nov;86(Pt 11):3009-19 [16227222.001]
  • [Cites] J Virol. 2005 Aug;79(16):10709-17 [16051863.001]
  • [Cites] J Virol. 1999 Dec;73(12):9827-31 [10559294.001]
  • [Cites] J Virol. 2000 Nov;74(21):10223-8 [11024153.001]
  • [Cites] Immunity. 2000 Oct;13(4):497-506 [11070168.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):420-4 [11208834.001]
  • [Cites] Int J Cancer. 2001 Sep15;93(6):810-6 [11519042.001]
  • [Cites] Cell Death Differ. 2002 Mar;9(3):287-300 [11859411.001]
  • [Cites] EMBO J. 2002 Mar 1;21(5):954-65 [11867523.001]
  • [Cites] Nat Rev Cancer. 2002 Oct;2(10):764-76 [12360279.001]
  • (PMID = 17001014.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Epstein-Barr Virus Nuclear Antigens; 0 / Proto-Oncogene Proteins c-myc; 0 / RNA, Messenger; 0 / Viral Matrix Proteins; 0 / Viral Proteins
  • [Other-IDs] NLM/ PMC1595454
  •  go-up   go-down


41. Hoxha FT, Hashani SI, Krasniqi AS, Kurshumliu FI, Komoni DS, Hasimja SM, Maxhuni M: Intussusceptions as acute abdomen caused by Burkitt lymphoma: a case report. Cases J; 2009;2:9322

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intussusceptions as acute abdomen caused by Burkitt lymphoma: a case report.
  • INTRODUCTION: Burkitt's lymphoma is a highly malignant, aggressive and rapidly growing B-cell neoplasm, which has low long-term survival rates.
  • The abdomen is the most frequent onset site of non endemic Burkitt's lymphoma.
  • Symptoms are often misleading and make diagnosis difficult.
  • Ileum intussusception as acute abdomen caused by Burkitt lymphoma is rare.
  • Following this was a second urgent operation of ileoileal intusussception caused by Burkitt lymphoma.
  • CONCLUSION: Affected terminal ileum by Burkitt's lymphoma may mimic clinically acute appendicitis and investigation tools sometimes may not provide proper diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Gastroenterol. 2009 Jan 28;15(4):407-11 [19152443.001]
  • [Cites] Am J Med. 1975 Mar;58(3):314-21 [1115074.001]
  • [Cites] Trop Doct. 2008 Jan;38(1):7-11 [18302850.001]
  • [Cites] Leuk Lymphoma. 2006 Apr;47(4):583-98 [16690516.001]
  • [Cites] Curr Opin Hematol. 2007 Jul;14(4):375-81 [17534164.001]
  • [Cites] Minerva Pediatr. 2006 Jun;58(3):311-8 [16832338.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3009-20 [15265787.001]
  • [Cites] Haematologica. 1997 May-Jun;82(3):305-8 [9234576.001]
  • [Cites] J Pediatr Surg. 1991 Nov;26(11):1273-5 [1812254.001]
  • [Cites] J Pediatr Surg. 1991 Oct;26(10):1235-8 [1779335.001]
  • [Cites] J Pediatr Surg. 1987 Jul;22(7):671-4 [3612465.001]
  • [Cites] Ann Surg. 1982 Jul;196(1):82-6 [7092357.001]
  • [Cites] Cancer. 1982 Mar 1;49(5):1016-22 [7059918.001]
  • [Cites] Br Med J. 1974 May 11;2(5914):308-12 [4827106.001]
  • [Cites] Cases J. 2008;1(1):15 [18577260.001]
  • (PMID = 20062585.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2803985
  •  go-up   go-down


42. Koffi GK, Tolo A, Nanho DC, N'dathz E, Kouassi MY, N'Diaye FD, Kouakou B, Meité N, Ayemou R, Sekongo M, Kouehion P, Meité M, Tea ND, Sangaré A, Sanogo I: Results of treatment with CMA, a low intermediate regimen, in endemic Burkitt lymphomas in sub-Saharian Africa: experience of Côte d'Ivoire. Int J Hematol; 2010 Jun;91(5):838-43
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of treatment with CMA, a low intermediate regimen, in endemic Burkitt lymphomas in sub-Saharian Africa: experience of Côte d'Ivoire.
  • African Burkitt lymphomas (BL) are highly aggressive lymphomas mainly affecting children and young adults in Africa.
  • This lymphoma was marked by its high sensitivity to chemotherapy in comparison to Sporadic Burkitt lymphoma.
  • Eighty-five of the 105 children registered were evaluated for response; there were 46 boys and 39 girls, whose age at diagnosis ranged from 3 to 18 years (median 11 years), admitted to the Hematology National Teaching Hospital of Abidjan in the period 1998-2008 with a diagnosis of BL on histological review and who were given CMA chemotherapy with curative intent are included in this analysis.
  • Fifty-three of patients were alive in first CR at a median survival rate period of 2 years (range 82 days to 9 years) and are continuously disease free from Burkitt lymphomas.
  • Twelve patients relapse after CR and died of lymphoma progression.
  • More than 32 patients died, as a result of lymphoma progression.
  • In conclusion, CMA protocol shows the high sensitivity of African Burkitt lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Cyclophosphamide / therapeutic use. Cytarabine / therapeutic use. Methotrexate / therapeutic use

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20480270.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


43. Müller AM, Ihorst G, Mertelsmann R, Engelhardt M: Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology. Ann Hematol; 2005 Jan;84(1):1-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology.
  • While for most cancers incidence and mortality are decreasing, those of non-Hodgkin's lymphoma (NHL) are steadily increasing.
  • Differences in geographic distribution are striking for follicular lymphoma, which is more common in Western countries than elsewhere.
  • Asians have higher rates of aggressive NHL, T-cell lymphomas, and extranodal disease.
  • In the Middle East, high rates of intestinal extranodal disease are observed, whereas in Africa, endemic Burkitt's lymphoma accounts for a substantial proportion.
  • Risks for developing NHL include immunosuppression and a causal link between infectious agents, and lymphomagenesis has also been determined, particularly for human T-cell leukemia/lymphoma virus type 1 (HTLV-1), Epstein-Barr virus (EBV), and Helicobacter pylori infections.
  • [MeSH-major] Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15480663.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  • [Number-of-references] 99
  •  go-up   go-down


44. Zauner L, Melroe GT, Sigrist JA, Rechsteiner MP, Dorner M, Arnold M, Berger C, Bernasconi M, Schaefer BW, Speck RF, Nadal D: TLR9 triggering in Burkitt's lymphoma cell lines suppresses the EBV BZLF1 transcription via histone modification. Oncogene; 2010 Aug 12;29(32):4588-98
Genetic Alliance. consumer health - Burkitt's Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TLR9 triggering in Burkitt's lymphoma cell lines suppresses the EBV BZLF1 transcription via histone modification.
  • Endemic Burkitt's lymphoma (BL) is considered to preferentially develop in equatorial Africa because of chronic co-infection with Epstein-Barr virus (EBV) and the malaria pathogen Plasmodium falciparum.
  • [MeSH-major] Burkitt Lymphoma / pathology. Herpesvirus 4, Human / genetics. Histones / metabolism. Toll-Like Receptor 9 / metabolism. Trans-Activators / genetics. Transcription, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20514021.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BZLF1 protein, Herpesvirus 4, Human; 0 / Hemeproteins; 0 / Histones; 0 / Ligands; 0 / Myeloid Differentiation Factor 88; 0 / Protozoan Proteins; 0 / Toll-Like Receptor 9; 0 / Trans-Activators; 39404-00-7 / hemozoin
  •  go-up   go-down


45. Rainey JJ, Mwanda WO, Wairiumu P, Moormann AM, Wilson ML, Rochford R: Spatial distribution of Burkitt's lymphoma in Kenya and association with malaria risk. Trop Med Int Health; 2007 Aug;12(8):936-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spatial distribution of Burkitt's lymphoma in Kenya and association with malaria risk.
  • Endemic Burkitt's lymphoma (BL) is the most common paediatric malignancy in equatorial Africa and was originally shown to occur at high-incidence rates in regions where malaria transmission is holoendemic.
  • Incidence rates varied by malaria transmission intensity as follows: low malaria risk (BL IR = 0.39), arid/seasonal (0.25), highland (0.66), endemic coast (0.68), and endemic lake (1.23) (chi(2) = 11.32, P = 0.002).
  • [MeSH-major] Burkitt Lymphoma / epidemiology. Endemic Diseases. Malaria / epidemiology

  • Genetic Alliance. consumer health - Malaria.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - Malaria.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17697088.001).
  • [ISSN] 1360-2276
  • [Journal-full-title] Tropical medicine & international health : TM & IH
  • [ISO-abbreviation] Trop. Med. Int. Health
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


46. Costes V: [Lymphoid lesions of the head and neck]. Ann Pathol; 2009 Sep;29(4):323-34
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Pathologie lymphoïde de la tête et du cou.
  • Waldeyer's ring, functionally similar to the mucosal associated lymphoid tissue of the gastrointestinal tract is most commonly affected by large B-cell lymphomas.
  • The nasal cavity and paranasal sinuses are the typical site of extranodal NK/T-cell lymphoma, nasal type, a proliferation of cytotoxic, EBV infected cells.
  • Plasmablastic lymphoma have been first described in oral cavity in HIV patients.
  • Endemic Burkitt lymphoma, considered as a polymicrobial disease associated with the t(14;18) translocation presented in the great majority of cases as a jaw tumor with oral extension.
  • It represents a pre lymphomatous state of marginal zone lymphoma.
  • [MeSH-major] Head and Neck Neoplasms / pathology. Lymphatic Diseases / pathology. Lymphoma / pathology

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Lymphatic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19900637.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


47. Sumba PO, Kabiru EW, Namuyenga E, Fiore N, Otieno RO, Moormann AM, Orago AS, Rosenbaum PF, Rochford R: Microgeographic variations in Burkitt's lymphoma incidence correlate with differences in malnutrition, malaria and Epstein-Barr virus. Br J Cancer; 2010 Nov 23;103(11):1736-41
MedlinePlus Health Information. consumer health - Malnutrition.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microgeographic variations in Burkitt's lymphoma incidence correlate with differences in malnutrition, malaria and Epstein-Barr virus.
  • BACKGROUND: Endemic Burkitt's lymphoma (eBL) has been associated with Epstein-Barr virus (EBV) and holoendemic Plasmodium falciparum malaria.

  • Genetic Alliance. consumer health - Malaria.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - Malaria.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2004 Mar 25;350(13):1328-37 [15044644.001]
  • [Cites] Cancer Res. 1967 Dec;27(12):2424-38 [4295479.001]
  • [Cites] Science. 1973 Feb 9;179(4073):588-90 [4686466.001]
  • [Cites] Trans R Soc Trop Med Hyg. 1998 Nov-Dec;92(6):601-6 [10326100.001]
  • [Cites] Nat Rev Microbiol. 2005 Feb;3(2):182-7 [15685227.001]
  • [Cites] J Infect Dis. 2005 Apr 15;191(8):1233-8 [15776368.001]
  • [Cites] Scand J Immunol. 2005 May;61(5):461-5 [15882438.001]
  • [Cites] Biol Trace Elem Res. 2005 Aug;106(2):107-15 [16116242.001]
  • [Cites] J Infect Dis. 2006 Apr 1;193(7):971-7 [16518759.001]
  • [Cites] Clin Chim Acta. 2006 Jul 15;369(1):100-3 [16500636.001]
  • [Cites] Int J Cancer. 2007 Jan 1;120(1):121-7 [17019706.001]
  • [Cites] Am J Clin Nutr. 2007 Jan;85(1):173-81 [17209194.001]
  • [Cites] Trop Med Int Health. 2007 Aug;12(8):936-43 [17697088.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2007;:277-84 [18024641.001]
  • [Cites] Lancet Oncol. 2008 Jul;9(7):683-92 [18598933.001]
  • [Cites] Pediatr Blood Cancer. 2008 Oct;51(4):495-8 [18636463.001]
  • [Cites] Pediatr Blood Cancer. 2008 Nov;51(5):626-8 [18668514.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Feb 17;106(7):2313-8 [19139406.001]
  • [Cites] Malar J. 2009;8:116 [19490641.001]
  • [Cites] Am J Respir Cell Mol Biol. 2009 Sep;41(3):348-57 [19151318.001]
  • [Cites] Cancer Res. 2009 Oct 15;69(20):8183-90 [19826042.001]
  • (PMID = 21102592.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / FIC NIH HHS / TW / 1D43TW006576; United States / FIC NIH HHS / TW / 5R03 TW007821; United States / FIC NIH HHS / TW / D43 TW006576; United States / FIC NIH HHS / TW / R03 TW007821; United States / NCI NIH HHS / CA / R01 CA102667
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] EC 1.11.1.9 / Glutathione Peroxidase
  • [Other-IDs] NLM/ PMC2994219
  •  go-up   go-down


48. Campidelli C, Gazzola A, Vitone F, Pileri SA, Tumwine L: HIV infection and c-MYC status in endemic Burkitt lymphoma. Hum Pathol; 2008 Sep;39(9):1408-9
MedlinePlus Health Information. consumer health - HIV/AIDS.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV infection and c-MYC status in endemic Burkitt lymphoma.
  • [MeSH-major] Burkitt Lymphoma / pathology. Genes, myc / genetics. HIV Infections / complications

  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18706352.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


49. Ribeiro RC, Sandlund JT: Burkitt lymphoma in African children: a priority for the global health agenda? Pediatr Blood Cancer; 2008 Jun;50(6):1125-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt lymphoma in African children: a priority for the global health agenda?
  • [MeSH-major] Burkitt Lymphoma / therapy. Developing Countries. International Cooperation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Pediatr Blood Cancer. 2008 Jun;50(6):1138-42 [18213709.001]
  • (PMID = 18300307.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA21765
  • [Publication-type] Comment; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


50. Mbulaiteye SM, Talisuna AO, Ogwang MD, McKenzie FE, Ziegler JL, Parkin DM: African Burkitt's lymphoma: could collaboration with HIV-1 and malaria programmes reduce the high mortality rate? Lancet; 2010 May 8;375(9726):1661-3
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] African Burkitt's lymphoma: could collaboration with HIV-1 and malaria programmes reduce the high mortality rate?
  • [MeSH-major] Burkitt Lymphoma / mortality. Government Programs. HIV Infections / therapy. HIV-1. International Cooperation. Malaria, Falciparum / therapy


51. Jacobs P, Wood L, Armitage JO: Proceedings of the 12th Biennial Congress -- South African Lymphoma Study Group. Transfus Apher Sci; 2007 Aug;37(1):27-9
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proceedings of the 12th Biennial Congress -- South African Lymphoma Study Group.
  • [MeSH-major] Lymphoma

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17881292.001).
  • [ISSN] 1473-0502
  • [Journal-full-title] Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • [ISO-abbreviation] Transfus. Apher. Sci.
  • [Language] eng
  • [Publication-type] Congresses; Editorial
  • [Publication-country] England
  •  go-up   go-down


52. Jacobs P, Wood L: Lymphoma--the immune system in disarray Theme for the 11th Congress of the South African Lymphoma Study Group meeting. Transfus Apher Sci; 2005 Feb;32(1):21-3
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoma--the immune system in disarray Theme for the 11th Congress of the South African Lymphoma Study Group meeting.
  • [MeSH-major] Immune System / pathology. Leukemia / immunology. Lymphoma / immunology. Lymphoproliferative Disorders / immunology

  • MedlinePlus Health Information. consumer health - Immune System and Disorders.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15737869.001).
  • [ISSN] 1473-0502
  • [Journal-full-title] Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • [ISO-abbreviation] Transfus. Apher. Sci.
  • [Language] eng
  • [Publication-type] Congresses; Editorial
  • [Publication-country] England
  •  go-up   go-down


53. Armitage JO, German Hodgkin Study Group, Diehl V, Engert A, Jacobs P, Groote Schuur Hospitals Teaching Group, Wood L: Proceedings of the 13th biennial South African Lymphoma Study Group Meeting--Cape Town October 2008. Transfus Apher Sci; 2010 Apr;42(2):125-8
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proceedings of the 13th biennial South African Lymphoma Study Group Meeting--Cape Town October 2008.
  • [MeSH-major] Lymphoma

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20219432.001).
  • [ISSN] 1473-0502
  • [Journal-full-title] Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • [ISO-abbreviation] Transfus. Apher. Sci.
  • [Language] eng
  • [Publication-type] Congresses; Editorial
  • [Publication-country] England
  •  go-up   go-down






Advertisement